NCT05910827 2026-04-15
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
Clinical Trials
71 trialsNCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06532032 2026-04-13
swalloWTail
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT06863272 2026-04-13
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05083481 2026-04-08
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT03917381 2026-04-06
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT05094336 2026-03-31
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
NCT06353386 2026-03-24
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT05904379 2026-03-09
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Akeso
Phase 1/2 Active not recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT06879717 2026-01-16
PULMO-01
iOnctura
Phase 1/2 Active not recruiting
NCT06568094 2025-12-31
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT06228326 2025-10-24
KYANITE-1
Krystal Biotech, Inc.
Phase 1/2 Recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07070440 2025-08-29
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT04256707 2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05062980 2025-02-20
Acclaim-2
Genprex, Inc.
Phase 1/2 Terminated
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06732531 2025-01-09
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2 Recruiting
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT06394713 2024-05-01
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT01234025 2023-10-06
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Ionis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT05027204 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT05235542 2022-08-11
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Akeso
Phase 1/2 Unknown
NCT02659020 2022-05-09
ANNOUNCE 2
Eli Lilly and Company
Phase 1/2 Completed
NCT05173142 2022-03-08
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
Hutchmed
Phase 1/2 Unknown
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT04430933 2021-08-18
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
Phase 1/2 Withdrawn
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed